Sun Pharma Advanced (SPARC) | Stock Overview & Key Data
Sun Pharma Advanced Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: ₹875.00 on April 24, 2006
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sun Pharma Advanced
SPARC
|
46.75B Small-cap | -13.30% | 46.20% | 62.20% | 26.84% | 51.26% | 14.56% | 13.10% | -5.14% | -23.02% | 148.11% | -27.03% |
|
Sun Pharmaceutical
SUNPHARMA
|
3.88T Large-cap | -2.77% | -1.84% | 2.13% | -0.53% | 4.00% | 7.25% | 79.99% | 166.96% | 144.01% | 669.48% | 2,278.32% |
|
Divi's Laboratories
DIVISLAB
|
1.69T Large-cap | -3.26% | -1.31% | 2.02% | 1.80% | 2.98% | 0.83% | 89.86% | 56.44% | 484.44% | 1,625.50% | 9,907.51% |
|
Innova Captab
INNOVACAP
|
41.43B Small-cap | 2.24% | 2.13% | 29.82% | 21.15% | 16.79% | -3.19% | 57.07% | 57.07% | 57.07% | 57.07% | 57.07% |
|
Gujarat Themis
GUJTHEM
|
35.41B Small-cap | 7.42% | 6.10% | 33.40% | -1.19% | -10.34% | 31.69% | 84.69% | 84.69% | 84.69% | 84.69% | 84.69% |
|
Aarti Drugs
AARTIDRUGS
|
33.96B Small-cap | -3.45% | -3.80% | 6.58% | -7.16% | -8.60% | -14.30% | -16.64% | -49.93% | 230.78% | 2,195.72% | 3,618.48% |
Ownership & Short Interest
Calculate Your Sun Pharma Advanced Investment Returns
Long-Term Investment Performance Analysis
Sun Pharma Advanced stock price in May 2016 was ₹275.55, A ₹1,000.00 lump sum investment in Sun Pharma Advanced made 10 years ago would be worth approximately ₹756.67 today, representing a negative return of -24.33%. This translates to an annualized return (CAGR) of -2.75%.
10 Years Investment Scenario (May 2016 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is SPARC's 52-week high and low?
- In the last 52 weeks, Sun Pharma Advanced reached a high of ₹248.75 (on May 26, 2026) and a low of ₹108.00 (on March 23, 2026).
- What is the market cap and P/E ratio for SPARC?
- Curious about Sun Pharma Advanced's size and valuation? Its market capitalization stands at 46.75B. When it comes to valuation, the P/E ratio (trailing twelve months) is -13.65, and the forward P/E (looking ahead) is 2.60.
- Does SPARC pay dividends? If so, what's the yield?
- As for dividends, Sun Pharma Advanced isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Sun Pharma Advanced's main competitors or similar companies to consider before investing?
When looking at Sun Pharma Advanced, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.88T Healthcare Drug Manufacturers - Specialty & Generic 7.25% 79.99% Divi's Laboratories
DIVISLAB1.69T Healthcare Drug Manufacturers - Specialty & Generic 0.83% 89.86% Innova Captab
INNOVACAP41.43B Healthcare Drug Manufacturers - Specialty & Generic -3.19% 57.07% Gujarat Themis
GUJTHEM35.41B Healthcare Drug Manufacturers - Specialty & Generic 31.69% 84.69% Aarti Drugs
AARTIDRUGS33.96B Healthcare Drug Manufacturers - Specialty & Generic -14.30% -16.64% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Sun Pharma Advanced Research Company Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Sun Pharma Advanced's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 157.88%, the Debt to Equity ratio from the most recent quarter is -1.21, and its Gross Profit Margin stands at -59.53%.
- What is the recent revenue and earnings growth for SPARC?
- Looking at Sun Pharma Advanced's growth, its revenue over the trailing twelve months (TTM) was INR531M. Compared to the same quarter last year (YoY), quarterly revenue grew by -43.30%, and quarterly earnings saw a YoY growth of -43.33%.
- How much of SPARC stock is held by insiders and institutions?
- Wondering who owns Sun Pharma Advanced stock? Company insiders (like executives and directors) hold about 72.96% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 2.56%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.